These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 21304506)

  • 41. Tumour necrosis factor alpha -308G->A polymorphism is not associated with response to TNFalpha blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis.
    Pavy S; Toonen EJ; Miceli-Richard C; Barrera P; van Riel PL; Criswell LA; Mariette X; Coenen MJ
    Ann Rheum Dis; 2010 Jun; 69(6):1022-8. PubMed ID: 19966089
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept.
    Ferreiro-Iglesias A; Montes A; Perez-Pampin E; Cañete JD; Raya E; Magro-Checa C; Vasilopoulos Y; Caliz R; Ferrer MA; Joven B; Carreira P; Balsa A; Pascual-Salcedo D; Blanco FJ; Moreno-Ramos MJ; Manrique-Arija S; Ordoñez MDC; Alegre-Sancho JJ; Narvaez J; Navarro-Sarabia F; Moreira V; Valor L; Garcia-Portales R; Marquez A; Gomez-Reino JJ; Martin J; Gonzalez A
    PLoS One; 2019; 14(2):e0213073. PubMed ID: 30818333
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity score.
    Gilani SS; Nair N; Plant D; Hyrich K; Morgan AW; Morris AP; Wilson AG; Isaacs JD; Barton A; Bluett J;
    Pharmacogenomics; 2020 Nov; 21(16):1151-1156. PubMed ID: 33124499
    [No Abstract]   [Full Text] [Related]  

  • 44. Deletion at 2q14.3 is associated with worse response to TNF-α blockers in patients with rheumatoid arthritis.
    Gu KN; Bang SY; Lee HS; Park Y; Kang JY; Kim JS; Nam B; Yoo HS; Shin JM; Lee YK; Lee TH; Chun S; Cho SK; Choi CB; Sung YK; Kim TH; Jun JB; Yoo DH; Kim K; Bae SC
    Arthritis Res Ther; 2019 Aug; 21(1):195. PubMed ID: 31462329
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Personalized medicine in rheumatoid arthritis: hopes and challenges.
    Bridges SL
    Bull NYU Hosp Jt Dis; 2007; 65(3):174-7. PubMed ID: 17922665
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association of MICA-129Met/Val polymorphism with clinical outcome of anti-TNF therapy and MICA serum levels in patients with rheumatoid arthritis.
    Iwaszko M; Świerkot J; Dratwa M; Wysoczańska B; Korman L; Bugaj B; Kolossa K; Jeka S; Wiland P; Bogunia-Kubik K
    Pharmacogenomics J; 2020 Dec; 20(6):760-769. PubMed ID: 32123296
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predictors of response to TNF inhibitors in rheumatoid arthritis - do we have new tools for personalized medicine?
    Simsek I
    Bull NYU Hosp Jt Dis; 2012; 70(3):187-90. PubMed ID: 23259626
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Biomarkers for prognosis of response to anti-TNF therapy of rheumatoid arthritis: Where do we stand?].
    Stuhlmüller B; Skriner K; Häupl T
    Z Rheumatol; 2015 Nov; 74(9):812-8. PubMed ID: 26347122
    [No Abstract]   [Full Text] [Related]  

  • 49. Personalized medicine: predicting responses to therapy in patients with RA.
    van den Broek M; Visser K; Allaart CF; Huizinga TW
    Curr Opin Pharmacol; 2013 Jun; 13(3):463-9. PubMed ID: 23578763
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis.
    Gonzalez-Gay MA; Garcia-Unzueta MT; De Matias JM; Gonzalez-Juanatey C; Garcia-Porrua C; Sanchez-Andrade A; Martin J; Llorca J
    Clin Exp Rheumatol; 2006; 24(4):373-9. PubMed ID: 16956426
    [TBL] [Abstract][Full Text] [Related]  

  • 51. TGF beta1 polymorphisms are candidate predictors of the clinical response to rituximab in rheumatoid arthritis.
    Daïen CI; Fabre S; Rittore C; Soler S; Daïen V; Tejedor G; Cadart D; Molinari N; Daurès JP; Jorgensen C; Touitou I
    Joint Bone Spine; 2012 Oct; 79(5):471-5. PubMed ID: 22129793
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Personalised treatment of arthritis in the next eRA.
    Tas SW
    Neth J Med; 2009 Dec; 67(11):362-3. PubMed ID: 20009111
    [No Abstract]   [Full Text] [Related]  

  • 54. Polymorphisms within the human leucocyte antigen-E gene and their associations with susceptibility to rheumatoid arthritis as well as clinical outcome of anti-tumour necrosis factor therapy.
    Iwaszko M; Świerkot J; Kolossa K; Jeka S; Wiland P; Bogunia-Kubik K
    Clin Exp Immunol; 2015 Dec; 182(3):270-7. PubMed ID: 26307125
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Application of omics in predicting anti-TNF efficacy in rheumatoid arthritis.
    Xie X; Li F; Li S; Tian J; Chen JW; Du JF; Mao N; Chen J
    Clin Rheumatol; 2018 Jan; 37(1):13-23. PubMed ID: 28600618
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Methotrexate pharmacogenetics in rheumatoid arthritis.
    Brinker RR; Ranganathan P
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S33-9. PubMed ID: 21044431
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacogenetics of etanercept: role of TNF-α gene polymorphisms in improving its efficacy.
    Murdaca G; Spanò F; Contatore M; Guastalla A; Magnani O; Puppo F
    Expert Opin Drug Metab Toxicol; 2014 Dec; 10(12):1703-10. PubMed ID: 25300969
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Brief Report: The Role of Rare Protein-Coding Variants in Anti-Tumor Necrosis Factor Treatment Response in Rheumatoid Arthritis.
    Cui J; Diogo D; Stahl EA; Canhao H; Mariette X; Greenberg JD; Okada Y; Pappas DA; Fulton RS; Tak PP; Nurmohamed MT; Lee A; Larson DE; Kurreeman F; Deluca TL; O'Laughlin M; Fronick CC; Fulton LL; Mardis ER; van der Horst-Bruinsma IE; Wolbink GJ; Gregersen PK; Kremer JM; Crusius JB; de Vries N; Huizinga TW; Fonseca JE; Miceli-Richard C; Karlson EW; Coenen MJ; Barton A; Plenge RM; Raychaudhuri S
    Arthritis Rheumatol; 2017 Apr; 69(4):735-741. PubMed ID: 27788309
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association of anti-CCP positivity and carriage of TNFRII susceptibility variant with anti-TNF-α response in rheumatoid arthritis.
    Vasilopoulos Y; Bagiatis V; Stamatopoulou D; Zisopoulos D; Alexiou I; Sarafidou T; Settas L; Sakkas L; Mamouris Z
    Clin Exp Rheumatol; 2011; 29(4):701-4. PubMed ID: 21813066
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-a blockade in patients with rheumatoid arthritis.
    Macías I; García-Pérez S; Ruiz-Tudela M; Medina F; Chozas N; Girón-González JA
    J Rheumatol; 2005 Nov; 32(11):2102-8. PubMed ID: 16265686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.